{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T01:38:20Z","timestamp":1761788300667,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12902-017-0219-x","type":"journal-article","created":{"date-parts":[[2017,11,6]],"date-time":"2017-11-06T05:49:22Z","timestamp":1509947362000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin"],"prefix":"10.1186","volume":"17","author":[{"given":"Seung-Hwan","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6565-7113","authenticated-orcid":false,"given":"Ira","family":"Gantz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Round","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Latham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward A.","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulette","family":"Ceesay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shailaja","family":"Suryawanshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith D.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel S.","family":"Engel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eseng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,6]]},"reference":[{"key":"219_CR1","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.2337\/diabetes.49.12.2063","volume":"49","author":"RS Hundal","year":"2000","unstructured":"Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes. 2000;49:2063\u20139.","journal-title":"Diabetes"},{"key":"219_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0029-1211414","volume":"104","author":"U Panten","year":"1996","unstructured":"Panten U, Schwanstecher M, Schwanstecher C. Sulfonylurea receptors and mechanism of sulfonylurea action. Exp Clin Endocrinol Diabetes. 1996;104:1\u20139.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"219_CR3","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1185\/030079906X162746","volume":"23","author":"RE Pratley","year":"2007","unstructured":"Pratley RE, Salsali A. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr Med Res Opin. 2007;23:919\u201331.","journal-title":"Curr Med Res Opin"},{"key":"219_CR4","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1021\/jm401992e","volume":"57","author":"T Biftu","year":"2014","unstructured":"Biftu T, Sinha-Roy R, Chen P, Qian X, Feng D, Kuethe JT, et al. Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once weekly treatment of type 2 diabetes. J Med Chem. 2014;57:3205\u201312.","journal-title":"J Med Chem"},{"key":"219_CR5","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med. 1999;130:461\u201370.","journal-title":"Ann Intern Med"},{"key":"219_CR6","first-page":"134","volume":"62","author":"KY Liang","year":"2000","unstructured":"Liang KY, Zeger SL. Longitudinal data analysis of continuous and discrete responses for pre-post designs. Indian J Stat. 2000;62:134\u201348.","journal-title":"Indian J Stat"},{"key":"219_CR7","first-page":"213","volume":"4","author":"O Miettinen","year":"1985","unstructured":"Miettinen O, Nurminen M. Comparative analysis of two rates. StatMed. 1985;4:213\u201326.","journal-title":"StatMed"},{"key":"219_CR8","doi-asserted-by":"crossref","DOI":"10.1002\/9780470316696","volume-title":"Multiple imputation for nonresponse in surveys","author":"DB Rubin","year":"1987","unstructured":"Rubin DB. Multiple imputation for nonresponse in surveys. New York: Wiley; 1987."},{"key":"219_CR9","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/j.1464-5491.2011.03387.x","volume":"28","author":"DR Owens","year":"2011","unstructured":"Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med. 2011;28:1352\u201361.","journal-title":"Diabet Med"},{"key":"219_CR10","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/dom.12229","volume":"16","author":"V Lukashevich","year":"2014","unstructured":"Lukashevich V, Del Prato S, Araga M, Kothny W. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea. Diabetes Obes Metab. 2014;16:403\u20139.","journal-title":"Diabetes Obes Metab"},{"key":"219_CR11","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/1753-0407.12351","volume":"8","author":"RG Moses","year":"2016","unstructured":"Moses RG, Round E, Shentu Y, Golm GT, O'Neill EA, Gantz I, et al. A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control. J Diabetes. 2016;8:701\u201311.","journal-title":"J Diabetes"},{"key":"219_CR12","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1463-1326.2007.00744.x","volume":"9","author":"K Hermansen","year":"2007","unstructured":"Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007;9:733\u201345.","journal-title":"Diabetes Obes Metab"},{"key":"219_CR13","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.2337\/dc06-0703","volume":"29","author":"P Aschner","year":"2006","unstructured":"Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29:2632\u20137.","journal-title":"Diabetes Care"},{"key":"219_CR14","doi-asserted-by":"crossref","unstructured":"Shankar RR, Inzucchi SE, Scarabello V, Gantz I, Kaufman KD, Lai E, et al. A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Curr Med Res Opin. 2017;33:1853\u201360.","DOI":"10.1080\/03007995.2017.1335637"},{"key":"219_CR15","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.2337\/dc06-0706","volume":"29","author":"B Charbonnel","year":"2006","unstructured":"Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29:2638\u201343.","journal-title":"Diabetes Care"},{"key":"219_CR16","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","volume":"27","author":"JB Buse","year":"2004","unstructured":"Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628\u201335.","journal-title":"Diabetes Care"},{"key":"219_CR17","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2337\/dc14-0666","volume":"38","author":"S Matthaei","year":"2015","unstructured":"Matthaei S, Bowering K, Rohwedder K, Grohl A, Parikh S, Study G. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial. Diabetes Care. 2015;38:365\u201372.","journal-title":"Diabetes Care"},{"key":"219_CR18","unstructured":"Boehringer Ingleheim Pharmaceuticals I. Linagliptin Medical Review. 2010. Available from URL: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/201280Orig1s000MedR.pdf . Accessed 5 Apr 2016."},{"key":"219_CR19","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/dom.12832","volume":"19","author":"R Goldenberg","year":"2017","unstructured":"Goldenberg R, Gantz I, Andryuk PJ, O'Neill EA, Kaufman KD, Lai E, et al. Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2017;19:394\u2013400.","journal-title":"Diabetes Obes Metab"},{"key":"219_CR20","doi-asserted-by":"crossref","unstructured":"Home P, Shankar RR, Gantz I, Iredale C, O'Neill EA, Jain L, et al. A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes. Diabetes Res Clin Pract. 2017; Accepted for publication (DIAB_2017_397).","DOI":"10.1016\/j.diabres.2017.10.018"},{"key":"219_CR21","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/dc15-0109","volume":"38","author":"WH Sheu","year":"2015","unstructured":"Sheu WH, Gantz I, Chen M, Suryawanshi S, Mirza A, Goldstein BJ, et al. Safety and efficacy of Omarigliptin (MK-3102), a novel once-weekly DPP-4 inhibitor for the treatment of patients with type 2 diabetes. Diabetes Care. 2015;38:2106\u201314.","journal-title":"Diabetes Care"},{"key":"219_CR22","first-page":"S55","volume":"57","author":"I Gantz","year":"2014","unstructured":"Gantz I, Okamoto T, Ito Y, Okuyama K, Engel SS. Effect of omarigliptin, a novel once-weekly DPP-4 inhibitor, in Japanese patients with type 2 diabetes: a placebo- and sitagliptin-controlled trial. Diabetologia. 2014;57:S55.","journal-title":"Diabetologia"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-017-0219-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,5]],"date-time":"2019-10-05T13:26:54Z","timestamp":1570282014000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-017-0219-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,6]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["219"],"URL":"https:\/\/doi.org\/10.1186\/s12902-017-0219-x","relation":{},"ISSN":["1472-6823"],"issn-type":[{"type":"electronic","value":"1472-6823"}],"subject":[],"published":{"date-parts":[[2017,11,6]]},"article-number":"70"}}